CNS 1145
Latest Information Update: 15 Oct 2002
At a glance
- Originator CeNeS Pharmaceuticals
- Class Antiparkinsonians; Neuroprotectants; Nootropics
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 15 Oct 2002 Discontinued for Neurological disorders (Prevention) in USA (unspecified route)
- 30 May 2001 Profile reviewed but no significant changes made
- 06 Dec 1996 No-Development-Reported for Neurological disorders (Prevention) in USA (Unknown route)